Autobahn’s elunetirom receives FDA fast track for adjunctive bipolar treatment

Autobahn Therapeutics has received fast track designation from the FDA for elunetirom, its lead CNS-directed thyroid hormone receptor agonist. Autobahn expects topline data from the ongoing Phase II AMPLIFY-BD trial in adjunctive bipolar depression in the second quarter of 2026. Elunetirom is designed to enhance neurobiological activity at CNS-TRs and reduce peripheral thyroid hormone-related risks. Credit: sasirin pamai / Shutterstock.com. Autobahn Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for elunetirom, its lead central nervous system (CNS)-directed thyroid hormone receptor agonist. Elunetirom is an oral, once daily, brain-penetrant CNS thyroid hormone receptor (CNS-TR) agonist…

Source: Pharmaceutical Technology